This ADC has been evaluated in phase I clinical trials in patients with advanced recurrent platinum-resistant ovarian cancer and has shown evidence of antitumor activity, particularly in patients whose tumors express high levels of MUC16 (51). Here, MUC16 is linked to ovarian carcinoma.